AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 81.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,808 shares of the biotechnology company’s stock after acquiring an additional 2,600 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in AnaptysBio were worth $195,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Values First Advisors Inc. acquired a new stake in AnaptysBio during the 3rd quarter worth $49,000. nVerses Capital LLC raised its stake in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio during the 1st quarter worth $38,000. Headlands Technologies LLC raised its stake in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 2,900 shares in the last quarter. Finally, Duncan Williams Asset Management LLC acquired a new position in AnaptysBio in the third quarter valued at $282,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ANAB shares. UBS Group upped their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. Finally, Guggenheim upped their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $55.73.

Insiders Place Their Bets

In related news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The stock was acquired at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by company insiders.

AnaptysBio Stock Down 28.0 %

NASDAQ ANAB opened at $22.18 on Thursday. The firm has a 50-day moving average price of $34.92 and a 200 day moving average price of $29.88. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31. The stock has a market capitalization of $605.94 million, a P/E ratio of -3.61 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.